EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudie

Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years

Jianwei Zhang iD, Pan Chi iD, Lishuo Shi iD, Long Cui, Jinbo Gao, Wanglin Li, Hongbo Wei iD, Longqing Cheng, Zonghai Huang iD, Guangfu Cai, Ren Zhao, Zhongcheng Huang und 15 weitere

Journal of Clinical Oncology · 20.02.2025 · 43 (6) · 633-640

DOI: 10.1200/jco-24-01676 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.02.2025. Verfasst von Jianwei Zhang und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Rectal Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present 10-year results of the phase Ⅲ FOWARC trial, which evaluated the efficacy of modified infusional fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with or without radiation compared with fluorouracil with radiation in patients with locally advanced rectal cancer. A total of 495 patients age 18-75 years with stage Ⅱ-Ⅲ rectal cancer were randomly assigned to three treatment arms: fluorouracil plus radiotherapy, mFOLFOX6 plus radiotherapy, or mFOLFOX6 alone, followed by surgery and adjuvant chemotherapy. With a median follow-up of 10 years, the 10-year disease-free survival (DFS) rates were 52.5%, 62.6%, and 60.5%, respectively ( P = .56). The 10-year locoregional recurrence (LR) rates were 10.8%, 8.0%, and 9.6% ( P = .57), and the 10-year overall survival (OS) rates were 65.9%, 72.3%, and 73.4% ( P = .90). Subgroup analysis identified ypTNM stage as a significant prognostic factor for DFS, LR, and OS ( P < .0001, P < .006, P < .0001, respectively). Patients achieving pathologic complete response had 10-year DFS, LR, and OS rates of 84.3%, 3.0%, and 92.4%, respectively. No significant difference was observed in long-term survival outcome between mFOLFOX6 with and without radiation and fluorouracil plus radiation. These results demonstrate that neoadjuvant mFOLFOX6 chemotherapy can be considered as a therapeutic option in LARC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsRectal NeoplasmsHumansFluorouracilLeucovorinMiddle AgedAdultFemaleMaleAgedNeoadjuvant TherapyOxaliplatinYoung AdultOrganoplatinum CompoundsFollow-Up StudiesAdolescentDisease-Free SurvivalNeoplasm StagingNeoplasm Recurrence, Local

Substanzen

FluorouracilLeucovorinOxaliplatinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Oncology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, The State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.
  • Department of Colorectal Surgery, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Clinical Research Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
  • Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.

ORCID-Profile: Jianwei Zhang, Pan Chi, Lishuo Shi, Hongbo Wei, Zonghai Huang, Yisheng Wei, Liang Kang, Xiaojian Wu, Ping Lan, Yanhong Deng

Zitieren

APA

Zhang, J., Chi, P., Shi, L., Cui, L., Gao, J., Li, W., Wei, H., Cheng, L., Huang, Z., Cai, G., Zhao, R., Huang, Z., Zhou, H., Wei, Y., Zhang, H., Zheng, J., Huang, Y., Cai, Y., Zhou, Z., …, & Deng, Y. (2025). Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. Journal of Clinical Oncology, 43(6), 633-640. https://doi.org/10.1200/jco-24-01676

Vancouver

Zhang J, Chi P, Shi L, Cui L, Gao J, Li W, et al. Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years. Journal of Clinical Oncology. 2025;43(6):633-640. doi:10.1200/jco-24-01676

BibTeX
@article{Zhang2025,
  author = {Zhang, Jianwei and Chi, Pan and Shi, Lishuo and Cui, Long and Gao, Jinbo and Li, Wanglin and Wei, Hongbo and Cheng, Longqing and Huang, Zonghai and Cai, Guangfu and Zhao, Ren and Huang, Zhongcheng and Zhou, Hongfeng and Wei, Yisheng and Zhang, Hao and Zheng, Jian and Huang, Yan and Cai, Yue and Zhou, Zhiyang and Kang, Liang and Huang, Meijin and Wu, Xiaojian and Peng, Junsheng and Ren, Donglin and Lan, Ping and Wang, Jianping and Deng, Yanhong},
  title = {Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {6},
  pages = {633--640},
  doi = {10.1200/jco-24-01676}
}
Kostenlos starten →